We are delighted to be able to share the latest update from the Taysha gene therapy programme. Highlights include the first person who received the higher dose has had no serious adverse side effects, they have the go ahead to dose the second patient with the higher dose and agreement reached to expand the trial into Canada. This is in addition to the paediatric trial scheduled for the UK.
You can read the full paper here.
Latest update from Taysha